Nkarta, Inc. (NKTX)
NKTXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$1.59
-0.1361 (-7.88%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $114.01m
- P/E
- –
- EPS, last 4 quarters
- $-1.73
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.48 to $3.72
- Average volume
- 875.5k
- Previous close
- $1.73
Analysts
6 coveringBuy5 buy, 1 hold, 0 sell
Targets a year out average $11.25, +606.7% from here
Earnings
next estimate $-0.4200Next report
Dec 2025
-15.6%
Mar 2026
+5.1%
Jun 2026
-38.5%
Sep 2026
-12.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$27.29m | -$30.96m | -$30.88m | -$43.13m |
| Net income | -$21.71m | -$27.41m | -$27.83m | -$40.37m |
News
8 latest- Nkarta, Inc. Announces Initial Clinical Data for NKX019 in Myositis and Systemic SclerosisFintel · 5 hours ago
- Nkarta, Inc. to Host Webcast to Discuss Initial Clinical Data for NKX019 at ACR Convergence 2026Fintel · 3 days ago
- Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials AdvanceMarketBeat · Sep 27, 2026
- Nkarta Posts Wider Loss In Q2; Provides Clinical Update On NKX019 RTTNews · Aug 11, 2026
- NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramZacks · Apr 17, 2026
- Nkarta Posts Narrower Loss in Q2The Motley Fool · Aug 13, 2025
- $NKTX stock is up 12% today. Here's what we see in our data.Quiver Quantitative · Jul 17, 2025
- Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed RTTNews · Jun 6, 2025
The company
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- nkartatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.